Skip to content
Alkem Laboratories logo

Alkem Laboratories

ALKEM NSE
₹5,216.50 −19.50 (−0.37%)
P/E
28.91
View as Markdown
MCP
Close 4 Nov 2026 ₹5,216.50 −427.00 −7.57% 1Y
Start ₹5,643.50

Key Fundamentals

MidcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
21.20%
Debt to Equity
0.15
EPS (TTM)
₹180.45
Book Value
₹1,155.87
Market Cap
—
P/E (TTM)
28.91
P/B
4.51
ROE
18.90%
Dividend Yield
1.01%
EBITDA
₹3,589 Cr
52W High
₹5,933.50
52W Low
₹4,811.00
Day Range
₹5,141.00 – ₹5,230.00
Volume
48,616

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

50 Average

Data confidence 100/100

Category scores

Quality
49
Average
Returns, margins, earnings quality 22% weight
Valuation
80
Strong
Cheap vs sector & own history 24% weight
Growth
33
Poor
Sales & profit trajectory 9% weight
Financial Health
59
Good
Solvency, leverage, coverage 9% weight
Momentum
12
Poor
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 26.3%

Weaknesses

2
  • The company has delivered a poor sales growth of 10.7% over past five years.
  • Promoter holding has decreased over last 3 years: -7.04%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish937
OscillatorsBearish432
Moving AveragesNeutral505

Key readings

RSI (14)
54.43
Neutral
MACD (12,26,9)
−23.12
Bullish
SMA (50)
5,210.54
Bullish
SMA (200)
5,434.24
Bearish

As of

Analyst Rating

Based on 20 analysts
BUY60%

12 of 20 analysts rate Buy, 6 Hold, 2 Sell.

As of

BUY
12
60%
HOLD
6
30%
SELL
2
10%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+11.61%
5Y+10.66%
3Y+8.25%
1Y+13.47%
TTM+13.36%

Net profit

Net profit growth by window
10Y+12.07%
5Y+7.76%
3Y+32.66%
1Y+6.14%
TTM−5.53%

Operating cash flow

Operating cash flow growth by window
10Y+10.46%
5Y+9.19%
3Y+5.28%
1Y+2.61%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+2.78 pp
5Y−1.50 pp
3Y+6.46 pp
1Y+1.06 pp
TTM+0.24 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹5,688 Cr
Mar 2018₹6,401 Cr
Mar 2019₹7,357 Cr
Mar 2020₹8,344 Cr
Mar 2021₹8,865 Cr
Mar 2022₹10,634 Cr
Mar 2023₹11,599 Cr
Mar 2024₹12,668 Cr
Mar 2025₹12,965 Cr
Mar 2026₹14,712 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹905 Cr
Mar 2018₹638 Cr
Mar 2019₹774 Cr
Mar 2020₹1,149 Cr
Mar 2021₹1,618 Cr
Mar 2022₹1,680 Cr
Mar 2023₹1,007 Cr
Mar 2024₹1,811 Cr
Mar 2025₹2,215 Cr
Mar 2026₹2,351 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹993 Cr +8.1% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 29 Oct 2026
AI opinion · based on fundamentals
Risk medium

Alkem Laboratories trades at ₹5,079 as of 2026-10-29 with a market cap of ₹60,727 Cr and a P/E (TTM) of 28.15x. The company carries minimal debt (D/E of 0.15) and has delivered a 3-year compounded profit CAGR of 32%, though TTM profit growth has flattened to 0% and the stock has declined 10% over the past year.

Bull Case 7
  • Very low leverage with a debt-to-equity ratio of just 0.15, providing significant financial flexibility and resilience through economic cycles
  • Consistent ROE profile averaging 18-19% across 3-year, 5-year, and 10-year horizons, with the last year at 19% and ROCE at 18.84% as of 2026-10-29
  • Strong 3-year compounded profit CAGR of 32%, indicating a period of meaningful earnings expansion
  • TTM compounded sales growth of 13% shows an acceleration relative to the 5-year sales CAGR of 11% and 3-year CAGR of 8%
  • Healthy dividend payout ratio of 26.3% with a current dividend yield of 1.04%, offering shareholders regular income
  • 10-year compounded sales and profit CAGRs both at 12%, reflecting a long track record of steady business growth
  • Trading 14.4% below its 52-week high of ₹5,933.50, which may indicate the recent correction has priced in some near-term headwinds
Bear Case 6
  • TTM compounded profit growth has decelerated sharply to 0% from the 3-year CAGR of 32%, signalling potential margin pressure or base-effect normalisation
  • Stock has delivered a negative 1-year return of -10%, underperforming while broader markets remained relatively stable
  • Promoter holding has decreased by 7.04% over the last 3 years, which may raise governance or confidence concerns among investors
  • 5-year compounded sales CAGR of roughly 10.7% is considered poor relative to peers in the Indian pharmaceutical space
  • P/E (TTM) of 28.15x is elevated given that trailing earnings growth has stalled at 0%, implying the stock is priced for a recovery that is yet to materialise
  • 5-year stock CAGR of only 6% and 5-year profit CAGR of 9% indicate that long-term shareholder returns have been modest relative to the broader market

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Alkem Laboratories is focused on leadership strengthening, appointing a new CEO with 26+ years of pharma experience and adding two senior operations/supply chain executives. No visible headwinds emerged in the recent news flow. The block deal at ₹5,274 suggests institutional interest at current levels. Near-term outlook hinges on how the refreshed leadership team executes on growth and operational efficiency.

Positives 2
  • New CEO with deep experience Nov 03

    Dr. Amrut Naik appointed CEO effective Nov 11, 2026, bringing 26+ years of global pharmaceutical business leadership. Board-approved appointment signals planned leadership continuity.

  • Senior management strengthened Oct 12

    Laxmikant Tiwari and Niles Vartak appointed to senior roles effective Oct 12, 2026, bolstering operations and supply chain leadership.

Neutral 1
  • ₹26.69 crore block deal on NSE Oct 12

    Approximately 50,611 shares changed hands at ₹5,274.00 per share in a large trade worth ₹26.69 crore. No directional signal; likely institutional rebalancing.

Quarterly Results

₹ Cr
ALKEM quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
2,968
3,440
3,324
2,936
3,032
3,415
3,374
3,144
3,371
4,001
3,737
3,603
3,740
Expenses
2,579
2,693
2,616
2,534
2,423
2,662
2,615
2,752
2,632
3,080
2,909
3,086
2,974
Operating Profit
389
747
708
402
609
753
759
391
739
921
828
517
766
OPM %
13%
22%
21%
14%
20%
22%
23%
12%
22%
23%
22%
14%
20%
Other Income
66
6
42
76
120
134
93
146
149
104
90
65
153
Interest
30
30
25
27
29
28
36
28
30
35
42
54
47
Depreciation
72
74
70
83
80
79
85
112
88
94
95
106
100
PBT
353
648
655
367
619
780
731
396
771
896
781
423
772
Tax %
18%
5%
8%
17%
11%
10%
12%
18%
13%
13%
16%
40%
32%
Net Profit
288
615
604
304
550
702
641
322
668
779
653
251
521
EPS (₹)
23.98
51.9
49.76
24.55
45.6
57.6
52.34
25.58
55.56
63.99
53.19
19.78
43.49

Profit & Loss

₹ Cr
ALKEM profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,674
4,905
5,688
6,401
7,357
8,344
8,865
10,634
11,599
12,668
12,965
14,712
15,081
Expenses
3,248
4,038
4,687
5,392
6,237
6,868
6,920
8,580
9,977
10,419
10,452
11,706
12,049
Operating Profit
427
866
1,001
1,009
1,120
1,476
1,945
2,054
1,622
2,249
2,512
3,007
3,032
OPM %
12%
18%
18%
16%
15%
18%
22%
19%
14%
18%
19%
20%
20%
Other Income
176
227
110
115
82
102
230
146
101
186
494
407
412
Interest
81
71
45
55
55
65
59
52
107
112
122
161
178
Depreciation
71
93
101
143
193
253
275
304
310
299
357
382
395
PBT
451
928
965
926
955
1,260
1,842
1,844
1,305
2,023
2,527
2,871
2,872
Tax %
13%
19%
6%
31%
19%
9%
12%
9%
23%
10%
12%
18%
—
Net Profit
392
752
905
638
774
1,149
1,618
1,680
1,007
1,811
2,215
2,351
2,204
EPS (₹)
32.75
62.02
74.61
52.77
63.61
94.26
133
138
82.31
150
181
193
180
Div. Payout %
12%
20%
20%
25%
25%
27%
23%
25%
61%
27%
25%
28%
—

Balance Sheet

₹ Cr
ALKEM balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
24
24
24
24
24
24
24
24
24
24
24
24
Reserves
2,975
3,668
4,444
4,840
5,415
6,137
7,353
8,614
9,021
10,288
11,961
13,796
Borrowings
1,306
658
659
998
944
1,616
1,707
2,668
1,397
1,418
1,381
2,047
Other Liabilities
986
1,184
1,440
1,803
1,824
2,169
2,435
2,763
3,315
3,844
4,325
4,991
Total Liabilities
5,291
5,534
6,568
7,664
8,208
9,946
11,519
14,069
13,757
15,575
17,691
20,858
Fixed Assets
1,374
1,450
1,797
2,284
2,530
2,908
2,793
2,902
2,683
2,873
2,852
3,871
CWIP
111
172
299
381
493
363
393
339
323
159
548
282
Investments
481
509
553
444
324
261
333
371
622
484
1,846
1,869
Other Assets
3,325
3,403
3,918
4,555
4,861
6,413
8,000
10,457
10,129
12,060
12,445
14,836
Total Assets
5,291
5,534
6,568
7,664
8,208
9,946
11,519
14,069
13,757
15,575
17,691
20,858

Cash Flow

₹ Cr
ALKEM cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
325
726
471
266
780
585
1,265
1,111
1,682
1,948
1,913
1,963
Investing
−235
205
−294
−351
−318
−737
−995
−1,433
120
−1,011
−1,288
−1,682
Financing
−52
−927
−138
85
−379
79
−272
380
−1,761
−1,145
−811
−503
Net Cash Flow
39
3
40
0
82
−73
−2
58
42
−207
−186
−222
Free Cash Flow
190
472
−163
−411
253
237
1,116
783
1,453
1,761
1,278
1,476
CFO/EBITDA
101
107
73
47
92
59
86
73
121
105
96
86

Ratios

ALKEM financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
52
42
46
62
62
72
66
65
67
65
69
74
Inventory Days
169
169
198
221
186
198
241
262
194
197
224
239
Days Payable
101
108
122
147
119
104
112
102
87
129
148
161
Cash Conversion Cycle
121
103
122
135
129
167
196
225
174
132
145
152
Working Capital Days
−52
13
34
40
55
44
48
31
66
135
123
123
ROCE %
12%
23%
21%
17%
16%
18%
22%
18%
14%
20%
20%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Alkem Laboratories insights

72 extracted metrics across FY09–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 49.70%
  • DIIs 22.82%
  • Public 16.93%
  • FIIs 10.32%
  • Others 0.22%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Alkem Laboratories

What does Alkem Laboratories Ltd do?
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
Where is Alkem Laboratories Ltd (ALKEM) listed?
Alkem Laboratories Ltd trades as ALKEM on the NSE and under code 539523 on the BSE.
Which sector does Alkem Laboratories Ltd belong to?
Alkem Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Alkem Laboratories Ltd?
Alkem Laboratories Ltd trades at a PE ratio of 28.91 as of 4 Nov 2026, on earnings per share of ₹180.45, against a book value of ₹1,155.87 per share.
What is the 52-week high and low of Alkem Laboratories Ltd?
Over the last 52 weeks Alkem Laboratories Ltd has traded between ₹4,811 and ₹5,933.5 as of 4 Nov 2026.
Does Alkem Laboratories Ltd pay dividends?
Alkem Laboratories Ltd has a dividend yield of 1.01%.
What is the Return on Equity (ROE) of Alkem Laboratories Ltd?
Alkem Laboratories Ltd reported a return on equity of 18.90%. Its debt-to-equity ratio is 0.15.

Company Information

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.

Website alkemlabs.com
CEO Mr. Basudeo Narian Singh
Employees 18,785
Listed 23 Dec 2015
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ALKEM.md for Alkem Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month